CFI-402257, a Potent and Selective TTK Inhibitor, in Solid Tumors and With Fulvestrant in Breast Cancer

This study will be evaluating the safety and tolerability of CFI-402257 in subjects with advanced solid tumors and in advanced breast cancer. The study is designed to build on encouraging data from another study and to obtain further safety, efficacy, pharmacokinetics (PK) and pharmacodynamics (PD) data of CFI-402257.

Inclusion criteria

Part A Escalation

• Have histological or cytological proof of advanced cancer that has progressed on at least 1 prior line of systemic therapy

Inclusion criteria

Part A Expansion

• Breast cancer patients positive for estrogen receptor and/or progesterone receptor and negative for HER2
• Must have previously received a CDK4/6 inhibitor
• No limit on lines of endocrine therapy
• Must have received no more than 1 line of cytotoxic chemotherapy
• Have measurable disease as per RECIST 1.1 guidelines.

Inclusion criteria

Part B

• Breast cancer patients positive for estrogen receptor and/or progesterone receptor and negative for HER2
• Must have previously received a CDK4/6 inhibitor
• Must have previously received no more than 1 line of endocrine therapy
• Must have received no more than 1 line of cytotoxic chemotherapy
• Have measurable disease as per RECIST 1.1 guidelines.

Exclusion criteria

All Parts

• Are pregnant or nursing.
• Have received chemotherapy, biological therapy, or investigational treatment less than 4 weeks (6 weeks for nitrosoureas or mitomycin C) prior to first dose of study drug. Have received radiotherapy less than 2 weeks prior to first dose of study drug.
• Received growth factors within 14 days prior to initiation of dosing of CFI-402257 or who will require ongoing treatment with growth factors
• Have active, acute, or clinically significant chronic infections.
• Have the following cardiovascular conditions

• Have uncontrolled severe hypertension
• Have symptomatic congestive heart failure
• Have active angina pectoris or recent myocardial infarction
• Have chronic atrial fibrillation or QTc of greater than 470 msec.
• Have had major surgery within 21 days of starting therapy.
• Primary central nervous system malignancies or known central nervous system metastasis.
• Being treated with full dose warfarin.
• Coagulopathy or any history of coagulopathy within the past 6 months, including history of deep vein thrombosis or pulmonary embolism.
• Patients must avoid the use of strong CYP3A4 inducers and inhibitors. CYP3A sensitive substrates, PgP, BCRP inhibitors
• Have had prior treatment with a TTK/MPS1 inhibitor.
• Part B only: Known bleeding disorder which would prohibit administration of fulvestrant.
• Part B only: Concomitant active malignancy other than ER+/HER2- advanced breast cancer.
• Part A only: Concomitant active malignancy other than primary malignancy
• Part B only: Had prior treatment with fulvestrant or agents with similar MoA